Berliton 600 Soft Capsules, 600 mg each, No. 30 (15 x 2)

In stock: 2
$95.00

Ingredients

Active ingredient: thioctic acid;

1 soft capsule contains 600 mg of thioctic acid;

Excipients: hard fat, medium-chain triglycerides;

capsule shell: non-crystallizing sorbitol solution, 70% (E 420); glycerin (85%); gelatin; titanium dioxide (E 171); carmine lac (E 120).

Dosage Form

Soft capsules.

Main physical and chemical properties: a soft, oblong, pink gelatin capsule containing a yellow paste-like mass.

Pharmacotherapeutic group

Other agents affecting the digestive system and metabolic processes.

ATC code A16A X01.

Pharmacological properties

Pharmacodynamics.

Thioctic acid is a vitamin-like substance produced in the body that acts as a coenzyme in the oxidative decarboxylation of α-ketoacids. Hyperglycemia caused by diabetes mellitus leads to the deposition of glucose on the matrix proteins of blood vessels and the formation of so-called advanced glycation end products. This process leads to a reduction in endoneural blood flow and endoneural hypoxia/ischemia, which is associated with increased formation of free oxygen radicals that damage peripheral nerves. A depletion of the antioxidant glutathione in peripheral nerves has also been observed.

In studies on rats, thioctic acid influenced the biochemical process caused by diabetes mellitus induced by streptozocin, reducing the formation of advanced glycation end products, improved endoneural blood flow, and increased the physiological levels of the antioxidant glutathione, which acts in nerves affected by the diabetic process in a manner similar to that of an antioxidant against free oxygen radicals. These effects demonstrate thioctic acid’s ability to improve peripheral nerve function. This applies to sensory disturbances in diabetic polyneuropathy, which may manifest as dysesthesias and paresthesias, such as a burning sensation, pain, numbness, or pins-and-needles sensations.

In 1995, a multicenter, placebo-controlled study was conducted to evaluate the efficacy of thioctic acid for the symptomatic treatment of diabetic polyneuropathy; the study provided evidence of thioctic acid’s beneficial effect on the following symptoms under investigation, such as a burning sensation, paresthesia, numbness, and pain.

Pharmacokinetics.

After oral administration, thioctic acid is rapidly absorbed. Due to extensive presystemic metabolism, the absolute bioavailability (compared to intravenous administration) of orally administered thioctic acid is approximately 20%. Due to rapid distribution into tissues, the half-life of thioctic acid in plasma is approximately 25 minutes. The relative bioavailability of thioctic acid following oral administration of solid dosage forms is over 60% compared to an oral solution. The maximum plasma concentration—approximately 4 μg/mL—was measured approximately 30 minutes after oral administration of 600 mg of thioctic acid. In animal studies (rats, dogs) using a radioactive label, it was found that the drug is predominantly excreted by the kidneys (80–90%), specifically in the form of metabolites. In humans, only a negligible amount of the intact substance is excreted in the urine. Biotransformation occurs primarily through oxidation of the side chain (β-oxidation) and/or via S-methylation of the corresponding thiols.

Thioctic acid interacts in vitro with metal ion complexes (e.g., cisplatin). Thioctic acid forms poorly soluble complexes with sugar molecules.

Indications

Paresthesias associated with diabetic polyneuropathy.

Contraindications

Hypersensitivity to thioctic acid or to any other component of the drug.

Interactions with Other Medications and Other Types of Interactions

The efficacy of cisplatin is reduced when administered concomitantly with Berlition® 600 capsules.

Thioctic acid is a metal chelator and therefore, according to the basic principles of pharmacotherapy, it should not be used concurrently with metal compounds (for example, with dietary supplements containing iron or magnesium, or with dairy products, as they contain calcium). If the total daily dose of Berlition® 600 capsules is taken 30 minutes before breakfast, dietary supplements containing iron and magnesium may be taken during the day or in the evening.

The glucose-lowering effect of insulin or oral antidiabetic agents may be enhanced; therefore, especially during the initial stage of treatment with thioctic acid, careful monitoring of blood glucose levels is indicated. To avoid symptoms of hypoglycemia, it may be necessary in some cases to reduce the dose of insulin or an oral antidiabetic agent.

Regular consumption of alcoholic beverages is a significant risk factor for the development and progression of neuropathy and, as such, may also interfere with the effectiveness of treatment with Berlition® 600 capsules. Therefore, patients with diabetic polyneuropathy are strongly advised to abstain from alcohol. This also applies to periods when treatment is not being administered.

Special Considerations for Use

The key factor in the effective treatment of diabetic polyneuropathy is optimal control of the patient’s blood sugar levels. At the start of treatment for polyneuropathy, regenerative processes may cause a temporary worsening of paresthesias, such as a tingling sensation. When thioctic acid is used in patients with diabetes, frequent monitoring of blood glucose levels is necessary. In some cases, it may be necessary to reduce the doses of antidiabetic medications to prevent the development of hypoglycemia.

Berliton® 600 capsules contain sorbitol; therefore, they should not be used by patients with the rare hereditary disorder fructose intolerance.

One case of autoimmune insulin syndrome (AIS) has been reported during treatment with thioctic acid. Patients with a specific genotype for HLA (human leukocyte antigen system), such as the HLA-DRB1*04:06 and HLA-DRB1*04:03 alleles, are more prone to developing AIS during treatment with thioctic acid. The HLA-DRB1*04:03 allele (odds ratio for potential AIS susceptibility: 1.6) is predominantly found among individuals of European descent; furthermore, its prevalence is higher in Southern Europe than in Northern Europe. The HLA-DRB1*04:06 allele (odds ratio for potential susceptibility to AIS = 56.6) is predominantly found among patients in Japan and Korea. The possibility of AIS developing in patients taking thioctic acid should be considered when making a differential diagnosis of spontaneous hypoglycemia (see the “Adverse Reactions” section).

Use During Pregnancy or Breastfeeding

Fertility.

Studies on reproductive toxicity have not revealed any evidence of an effect on fertility.

Pregnancy.

Berliton® 600 capsules should be used during pregnancy only after a careful assessment of the benefit-risk ratio.

Breastfeeding.

There are no data on the excretion of thioctic acid or its metabolites into breast milk. A decision must be made regarding whether to discontinue breastfeeding or discontinue use of Berlition® 600 capsules, taking into account the benefits of breastfeeding for the infant and the benefits of therapy for the woman.

Effect on reaction time when driving or operating machinery

During treatment, caution should be exercised when driving, operating machinery, or engaging in other potentially hazardous activities that require increased attention and rapid psychomotor reactions, due to the possibility of side effects such as hypoglycemia, dizziness, and visual disturbances.

Dosage and Administration

Adults.

Dosage

The daily dose is 1 capsule of the medicinal product Berliton® 600 (equivalent to 600 mg of thioctic acid), which should be taken as a single dose approximately 30 minutes before the first meal of the day. In cases of severe paresthesias, treatment may be initiated with thioctic acid infusion therapy.

Directions for Use

Berliton® 600 capsules should be taken on an empty stomach, swallowed whole, and washed down with a sufficient amount of liquid. Taking the medication with food may impair absorption; therefore, it is particularly important for patients with delayed gastric emptying to take the medication half an hour before breakfast. Since diabetic polyneuropathy is a chronic condition, long-term therapy may be necessary. Optimal diabetes control is the cornerstone of treatment for diabetic polyneuropathy.

Children

Berliton® 600 capsules are not indicated for the treatment of children and adolescents due to a lack of clinical experience.

Overdose

Overdose may cause nausea, vomiting, and headache. Following accidental ingestion or a suicide attempt involving oral administration of thioctic acid in doses ranging from 10 g to 40 g in combination with alcohol, severe intoxication has been observed, in some cases with fatal consequences. In the initial stage, the clinical picture of intoxication may manifest as psychomotor agitation or impaired consciousness and is usually accompanied by the subsequent onset of generalized seizures and the development of lactic acidosis. In addition, the following have been described as consequences of intoxication with high doses of thioctic acid: hypoglycemia, shock, rhabdomyolysis, hemolysis, disseminated intravascular coagulation (DIC), bone marrow suppression, and multiple organ failure.

Treatment. Even if severe poisoning with the drug Berliton® 600 capsules is merely suspected (for example, ingestion of more than 10 capsules of 600 mg each for adults or doses exceeding 50 mg/kg of body weight for children), immediate hospitalization and measures in accordance with general principles of poisoning treatment (e.g., induction of vomiting, gastric lavage, administration of activated charcoal, etc.) are indicated. Treatment of generalized seizures, lactic acidosis, and other life-threatening consequences of intoxication should be guided by the principles of modern intensive care and administered symptomatically. To date, the efficacy of hemodialysis, hemoperfusion, or filtration methods for the forced elimination of thioctic acid has not been confirmed.

Side Effects

The following classification was used to assess the frequency of adverse events:

very common: ≥ 1/10;

common: ≥ 1/100 – < 1/10;

uncommon: ≥ 1/1,000 – < 1/100;

rare: ≥ 1/10,000 – < 1/1,000;

very rare: < 1/10,000;

unknown: cannot be estimated from the available data.

Immune system disorders.

Very rare: allergic reactions, including skin rashes, hives (urticaria), itching, and difficulty breathing.

Unknown: autoimmune insulin syndrome (see the “Special Considerations for Use” section), eczema.

Metabolic and nutritional disorders.

Very rare: hypoglycemia.

Nervous system disorders.

Common: dizziness.

Very rare: dysgeusia, headache, hyperhidrosis.

Eye disorders.

Very rare: visual disturbances.

Gastrointestinal disorders.

Common: nausea.

Very rare: vomiting, gastrointestinal pain, diarrhea.

General disorders.

Very rare: decreased blood glucose levels associated with improved glucose utilization. Symptoms similar to hypoglycemia: dizziness, sweating, headache, and visual disturbances.

Reporting of Suspected Adverse Reactions.

Reporting suspected adverse reactions after a drug’s approval is important. This allows for continued monitoring of the drug’s benefit-risk profile. Healthcare professionals are asked to report any suspected adverse reactions.

Shelf life

3 years.

Storage conditions

Store at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

15 capsules per blister pack; 1 or 2 blister packs per cardboard box;

10 capsules per blister pack; 3 blister packs per cardboard box.

Dispensing Category

By prescription only.

Manufacturer

BERLIN-CHEMIE AG.